- $0.45m
- $0.45m
- $2.55m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.01 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -84.39% | ||
| Return on Equity | -138.1% | ||
| Operating Margin | -1362.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.7 | 0.75 | 2.28 | 2.56 | 2.55 | n/a | n/a | 32.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
Directors
- Christopher Fashek NEC (71)
- Brian Murphy CEO (64)
- Stephen Brown CFO (65)
- Harold Jacob OTH (67)
- Aurora Cassirer IND
- Michael Ferguson IND (50)
- Martin Goldstein IND (53)
- Thomas Mika IND (69)
- Maria Schroeder IND
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 20th, 2003
- Public Since
- April 24th, 2015
- No. of Shareholders
- 103
- No. of Employees
- 12
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 923,718
- Address
- 969 Pruitt Place, TYLER, 75703
- Web
- https://envuemed.com
- Phone
- +1 9142333004
- Auditors
- Kost, Forer, Gabbay & Kasierer
Latest News for FEED
Upcoming Events for FEED
Q3 2026 ENvue Medical Inc Earnings Release
Nanovibronix Inc Annual Shareholders Meeting
Similar to FEED
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 02:30 UTC, shares in ENvue Medical are trading at $0.49. This share price information is delayed by 15 minutes.
Shares in ENvue Medical last closed at $0.49 and the price had moved by -99.37% over the past 365 days. In terms of relative price strength the ENvue Medical share price has underperformed the S&P500 Index by -99.45% over the past year.
The overall consensus recommendation for ENvue Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreENvue Medical does not currently pay a dividend.
ENvue Medical does not currently pay a dividend.
ENvue Medical does not currently pay a dividend.
To buy shares in ENvue Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.49, shares in ENvue Medical had a market capitalisation of $0.45m.
Here are the trading details for ENvue Medical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: FEED
Based on an overall assessment of its quality, value and momentum ENvue Medical is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ENvue Medical is $10.50. That is 2042.86% above the last closing price of $0.49.
Analysts covering ENvue Medical currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ENvue Medical. Over the past six months, its share price has underperformed the S&P500 Index by -97.54%.
As of the last closing price of $0.49, shares in ENvue Medical were trading -96.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ENvue Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ENvue Medical's management team is headed by:
- Christopher Fashek - NEC
- Brian Murphy - CEO
- Stephen Brown - CFO
- Harold Jacob - OTH
- Aurora Cassirer - IND
- Michael Ferguson - IND
- Martin Goldstein - IND
- Thomas Mika - IND
- Maria Schroeder - IND